Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | COM902 |
Synonyms | |
Therapy Description |
COM902 is a monoclonal antibody that targets and binds to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), inhibiting the interaction between TIGIT and its ligand CD155, leading to increased interaction of the TIGIT-ligands, CD112 and CD155, with the co-stimulatory receptor CD226 and activation of downstream signaling, which may result in an anti-tumor immune response (PMID: 33903974). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
COM902 | COM-902|COM 902 | TIGIT Antibody 19 | COM902 is a monoclonal antibody that targets and binds to the T-cell immunoreceptor with Ig and ITIM domains (TIGIT), inhibiting the interaction between TIGIT and its ligand CD155, leading to increased interaction of the TIGIT-ligands, CD112 and CD155, with the co-stimulatory receptor CD226 and activation of downstream signaling, which may result in an anti-tumor immune response (PMID: 33903974). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04354246 | Phase I | COM902 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | Recruiting | USA | 0 |